Daratumumab (Darzalex) — Clinical FAQs

Question 1

What is Daratumumab FDA-approved to treat?

Accepted Answer

Daratumumab is FDA-approved for the following oncology indications: 1. Multiple myeloma — newly diagnosed, transplant-eligible (D-VTd: daratumumab + bortezomib + thalidomide + dexamethasone) 2. Multiple myeloma — newly diagnosed, transplant-ineligible (D-Rd: daratumumab + lenalidomide + dexamethasone; D-VMP) 3. Multiple myeloma — relapsed/refractory (D-Rd; D-Vd; D-Pd; daratumumab monotherapy after ≥3 prior lines) 4. Light-chain (AL) amyloidosis — newly diagnosed (with bortezomib, cyclophosphamide, dexamethasone).

Question 2

How does Daratumumab work (mechanism of action)?

Accepted Answer

Human IgG1κ monoclonal antibody targeting CD38, a type II transmembrane glycoprotein highly expressed on multiple myeloma cells (and more modestly on normal plasma cells and some hematopoietic progenitors). Daratumumab eliminates myeloma cells via multiple mechanisms: complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and induction of apoptosis via Fc-mediated crosslinking. Additionally, daratumumab depletes CD38+ immunosuppressive regulatory T cells (Tregs), regulatory B cells (Bregs), and myeloid-derived suppressor cells — restoring anti-tumor T cell immunity. This immune-restoring mechanism may contribute to the deep and durable responses observed.

Question 3

How is Daratumumab administered?

Accepted Answer

Daratumumab is administered Intravenous (IV) or Subcutaneous (SC). IV (Darzalex): Dilute in NS 500–1000 mL; infuse over 7+ hours for first infusion, progressively shorter for subsequent infusions.

Question 4

What are the most common side effects of Daratumumab?

Accepted Answer

The most commonly reported side effects of Daratumumab (≥10% incidence) include: Infusion reactions (50% IV, ~10% SC — mostly Cycle 1), Fatigue, Nausea, Back pain, Neutropenia (especially in combination regimens) and others (8 total). Consult your oncologist for complete prescribing information.

Question 5

Does Daratumumab have a black box warning?

Accepted Answer

Yes. Daratumumab carries FDA black box warning(s) regarding: 1. Infusion reactions: severe reactions including bronchospasm, dyspnea, laryngeal edema, pulmonary edema, and hypoxia. Most occur during the first infusion. Pre-medicate and monitor closely. Post-infusion, monitor patients for at least 1 hour. 2. Interference with blood compatibility testing: daratumumab binds to CD38 on red blood cells, causing pan-agglutination in indirect antiglobulin testing (indirect Coombs). Blood banks must be notified before initiating therapy; genotype red blood cells and screen for alloantibodies before first infusion.

Question 6

Is Daratumumab safe during pregnancy?

Accepted Answer

Daratumumab pregnancy safety: May cause fetal harm (fetal immune B-cell depletion via CD38 targeting). Contraception required during and for 3 months after last dose.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Daratumumab — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms